Highlights of the PET CT

Unique Technical Features

• Latest Generation PET.CT with ultrafast LSO Crystal Technology.
• Scans entire body and provides fused images of the PET and CT (Anatometabolic Imaging).
• World’s Best PET resolution (2mm) for detection of smallest tumors.
• Accurate SUV (System Uptake Value) quantification and full HD lesion detection with motion-frozen images.
• High performance Spiral CT scanner with HRCT, 3D CT, CT Angiography, Dental C.T and CT Endoscopy.

Clinical Benefits

• Helps in early detection and accurate staging of cancer.
• Helps to take accurate guided biopsy samples from the suspected cancer lesions and relapsed lesions.
• Helps in early evaluation of response to therapy.
• Helps in accurate analysis of cancer treatment and follow up.
• Helps in early diagnosis of Dementias and Epilepsies.

Patient’s Comfort and Safety

• Provides enhanced Patient Comfort with high speed acquisition and lower retake exams due to improved image quality.
• No claustrophobia because of wide gantry aperture and slim table.
• Provides enhanced Patient safety with fully automated real-time dose modulation. Upto 65% dose reduction with full diagnostic image quality.

PET CT indications

• Staging of cancer which potentially can be treated radically e.g. small cell lung cancer
• Establish baseline staging before commencing treatment e.g. GIST
• Evaluation of an indeterminate lesion e.g. solitary lung nodule
• Assessing response to therapy
• Evaluation of suspected disease recurrence / relapse / residual disease e.g. lymphoma, testicular seminoma
• To guide biopsy e.g. pleural biopsy for mesothelioma

PET CT as an Aid

• Occult primary lesion e.g. non-metastatic manifestation of neoplastic disease.
• Evaluation of suspected recurrence in patients with equivocal conventional imaging
• Evaluation of residual disease with negative/ equivocal conventional imaging - in patients with treated differentiated thyroid carcinoma and treated medullary thyroid carcinoma.
• Prior knowledge to radical nodal resection - in patients with metastatic melanoma.
• Suspected malignant transformation - in plexiform neurofibromata (type 1 neurofibromatosis)
• Differentiate between radiation-induced necrosis and tumor recurrence e.g. brain tumors
• PUO (Pyrexia of unknown origin) for more than three weeks to aid in identification on disease origin.